期刊文献+

Benefits and risks of erythrocyte-stimulating agents

Benefits and risks of erythrocyte-stimulating agents
下载PDF
导出
摘要 Chronic kidney disease(CKD)is a common and serious clinical problem.Anemia in patients with advanced CKD,frequently called renal anemia,causes disabling fatigue and diminishes patients’quality of life.Frequent and excess transfusions or iron supplementation are potentially hazardous.Although it remains unclear whether the main factor in the development of renal anemia is the failure of erythropoietin(EPO)production in the kidney or a dysfunction in oxygen sensing exogenous EPO administration is considered a rational treatment.The advent of recombinant human erythropoietin(r Hu-EPO)products has dramatically changed the therapeutic strategy for renal anemia.Although rH u-EPO therapy has improved patients’quality of life and decreased the need for blood transfusions,some potential adverse effects have been reported till date.This brief review discusses the treatment of renal anemia with regard to the following:(1)historical background;(2)effectiveness of r Hu-EPO;(3)some topics regarding the treatment of anemia,including EPO resistance,hemoglobin(Hb)cycling,and adequate Hb levels;(4)major adverse effects of rH u-EPO,including hypertension,thrombotic complications,and pure red cell aplasia;and(5)future problems to be resolved. Chronic kidney disease(CKD)is a common and serious clinical problem.Anemia in patients with advanced CKD,frequently called renal anemia,causes disabling fatigue and diminishes patients’quality of life.Frequent and excess transfusions or iron supplementation are potentially hazardous.Although it remains unclear whether the main factor in the development of renal anemia is the failure of erythropoietin(EPO)production in the kidney or a dysfunction in oxygen sensing exogenous EPO administration is considered a rational treatment.The advent of recombinant human erythropoietin(r Hu-EPO)products has dramatically changed the therapeutic strategy for renal anemia.Although rH u-EPO therapy has improved patients’quality of life and decreased the need for blood transfusions,some potential adverse effects have been reported till date.This brief review discusses the treatment of renal anemia with regard to the following:(1)historical background;(2)effectiveness of r Hu-EPO;(3)some topics regarding the treatment of anemia,including EPO resistance,hemoglobin(Hb)cycling,and adequate Hb levels;(4)major adverse effects of rH u-EPO,including hypertension,thrombotic complications,and pure red cell aplasia;and(5)future problems to be resolved.
出处 《World Journal of Clinical Urology》 2014年第3期258-263,共6页 世界临床泌尿杂志
关键词 Chronic kidney disease Erythrocyte-stimulating AGENTS RENAL ANEMIA ERYTHROPOIETIN Pure red cell APLASIA Chronic kidney disease Erythrocyte-stimulating agents Renal anemia Erythropoietin Pure red cell aplasia
  • 相关文献

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部